Activation of AMPK suppresses glucose production in the liver and improves hyperglycemia in these patients (11, 12, 22, 47); therefore, AMPK is an ideal therapeutic target for treating T2DM and obesity. This evidence concerns the gene PRKAA2 and obesity due to melanocortin 4 receptor deficiency.